Program

Session 1: Genes and Pathways in Cancer

Chairperson: Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA
9:00 a.m.-12:00 p.m.

Molecular characterization of circulating tumor cells
Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA

From chromosome engineering to chromatin remodeler: CHD5 is a tumor suppressor mapping to human 1p36
Alea A. Mills, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

New cancer targets emerging from studies of the VHL tumor suppressor gene
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, MA

PI3-Kinase and cancer metabolism
Lewis C. Cantley, Beth Israel Deaconess Medical Center, Boston, MA

Mentoring Lunches for Early-Career Investigators

12:00 p.m.-1:30 p.m.

Session 2: Mouse Models of Cancer

Chairperson: Guillermina Lozano, UT M. D. Anderson Cancer Center, Houston, TX
1:30 p.m.-3:45 p.m.

The regulation of p53 tumor suppressing activities
Guillermina Lozano

Studying tumor evolution in mouse models of cancer
Tyler E. Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

Dissecting tumor suppressor gene networks in vivo
Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Special Lecture: Host-Germline Genetics

3:45 p.m.-4:30 p.m.

Single nucleotide polymorphisms in the p53 pathway
Arnold J. Levine, Institute for Advanced Study, Princeton, NJ

Special Lecture: Epigenetics

Chairperson: Elizabeth H. Blackburn, University of California, San Francisco, CA
4:45 p.m.-5:30 p.m.

Cancer, stem cells, and the epigenetic terrain
Stephen B. Baylin, Johns Hopkins University School of Medicine, Baltimore, MD

Poster Session A and Opening Reception

5:30 p.m.-7:30 p.m.

Session 3: Structural Biology

Chairperson: Arnold J. Levine, Institute for Advanced Study, Princeton, NJ
9:00 a.m.-11:15 a.m.

Protein phosphatase 2A: New insights into an old paradigm
Yigong Shi, Princeton University, Princeton, NJ

Fragment-based cancer drug discovery
Stephen W. Fesik, Vanderbilt University School of Medicine, Nashville, TN

p53: From structure to drug discovery
Alan R. Fersht, University of Cambridge, Cambridge, United Kingdom

Special Lecture: Mouse Models of Cancer

11:15 a.m.-12:00 p.m.

Using switchable mouse genetic models to validate therapeutic cancer targets
Gerald I. Evan, UCSF Comprehensive Cancer Center, San Francisco, CA

Mentoring Lunches for Early-Career Investigators

12:00 p.m.-1:30 p.m.

Session 4: Targeted Small Molecules

Chairperson: Julian Adams, Infinity Pharmaceuticals, Inc., Cambridge, MA
1:30 p.m.-4:30 p.m.

Examining the scale and scope of tools and programs to navigate in translational oncology space: Lessons learned
Stephen H. Friend, Sage Bionetworks, Seattle, WA

Discovery and preclinical activity of IPI-926, a Hedgehog pathway inhibitor
Julian Adams

Title to be announced
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

Oncology drug discovery and development in the 21st century
William N. Hait, Ortho Biotech Oncology Research and Development, a unit of Johnson and Johnson Research and Development, L.L.C., Raritan, NJ

Special Session: Systems Biology

Chairperson: Arnold J. Levine, Institute for Advanced Study, Princeton, NJ
4:45 p.m.-5:30 p.m.

Haplotype analysis of the p53 pathway
Gurinder Atwal, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

Poster Session B

5:30 p.m.-7:30 p.m.

Session 5: Cell Culture Systems and Stem Cells

Chairperson: Joan S. Brugge, Harvard Medical School, Boston, MA
9:00 a.m.-12:00 p.m.

Mechanisms regulating anchorage independent survival
Joan S. Brugge

Molecular alterations that predict premalignancy in breast cancer
Thea D. Tlsty, UCSF Comprehensive Cancer Center, San Francisco, CA

Common mechanisms of dedifferentiation in reprogramming and cancer
George Q. Daley, Children's Hospital, Boston, MA

Balancing quiescence and proliferation in stem cells and its implications for cancer
Elaine V. Fuchs, Howard Hughes Medical Institute, The Rockefeller University, New York, NY

Mentoring Lunches for Early-Career Investigators

12:00 p.m.-1:30 p.m.

Session 6: Metabolism and Cancer

Chairperson: Steven L. McKnight, UT Southwestern Medical Center, Dallas, TX
1:30 p.m.-4:30 p.m.

Control of growth by mTOR signaling
David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, MA

Survival pathways in tumors under metabolic stress
Tak W. Mak, Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, Toronto, ON, Canada

The roles of prolyl hydroxylases in metabolism and cancer
Eyal Gottlieb, Cancer Research UK, Beatson Institute for Cancer Research, Glasgow, United Kingdom

Mouse embryonic stem cells exist in a unique metabolic state
Steven L. McKnight

Special Lecture: MiRNA

Chairperson: Joan S. Brugge, Harvard Medical School, Boston, MA
4:45 p.m.-5:30 p.m.

MicroRNAs in cancer pathogenesis
Carlo M. Croce, Ohio State University Comprehensive Cancer Center, Columbus, OH

Poster Session C

5:30 p.m.-7:30 p.m.

Session 7: Metastasis

Chairperson: Robert A. Weinberg, Whitehead Institute for Biomedical Research, Cambridge, MA
9:00 a.m.-10:30 a.m.

Deconstructing metastasis
Joan Massagué, Memorial Sloan-Kettering Cancer Center, New York, NY

EMT in tumor invasion and metastasis
Thomas Brabletz, University of Freiburg, Freiburg, Germany

Malignant progression and the stem-cell state
Robert A. Weinberg

Session 8: Telomeres and DNA Damage Responses

Chairperson: Elizabeth H. Blackburn, University of California, San Francisco, CA
11:00 a.m.-12:00 p.m.

Cellular responses to telomerase perturbations
Elizabeth H. Blackburn

TERT, senescence, and transformation
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

Departure